

Special Issue

Personalized Medicine in Hypertension

Message from the Guest Editors

High blood pressure is still the leading risk factor for death and disability worldwide. Patients at high cardiovascular risk require intensive drug therapy for controlling blood pressure and other risk factors. The current therapeutic approach is based on the results of several clinical trials, assuming that subjects have common phenotypes and following algorithms derived from large population studies. This “one size fits all” approach improved hypertension control in the general population, requiring little or no information about individuals, and requires low medical investment. While this is the case, hypertension control is far from being satisfactory globally, and other strategies are required for its management. A personalized approach to hypertension is based on information that integrates data from clinical research, systems biology, ‘omics’ technologies, imaging findings, and e-technology, together with a patient’s involvement in clinical care. This could implement knowledge of the specific disease pathophysiology of patients and peculiar responses to treatment.

Guest Editors

Dr. Davide Agnoletti

Department of Medical and Surgical Sciences, University of Bologna, 40138 Bologna, Italy

Prof. Dr. Jacques Blacher

1. AP-HP, Diagnosis and Therapeutic Center, Faculty of Medicine, Hôtel-Dieu Hospital, Paris-Descartes University, 75004 Paris, France
2. UREN (Nutritional Epidemiology Research Unit)—U557 INSERM, U1125 INRA, CNAM, CRNH IdF, Paris 13, Sorbonne Paris Cité University, 93000 Bobigny, France

Deadline for manuscript submissions

closed (5 June 2023)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/126389

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

[mdpi.com/journal/
jpm](https://mdpi.com/journal/jpm)





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



[mdpi.com/journal/
jpm](https://mdpi.com/journal/jpm)



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM), ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).